IOL Chemicals & Pharmaceuticals Ltd (IOLCP) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by IOL Chemicals & Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Audio Recording of Earnings Call on the Q2 & H1 FY 27 Financial Results
Audio / Video · 02 Nov 2026, 8:58 pm
IOL Chemicals Releases Audio Recording for Q2 & H1 FY27 Earnings Call IOL Chemicals and Pharmaceuticals Limited has released the audio recording of its earnings call conducted on 2nd Nov'26. The call discussed the company's financial performance for Q2 & H1 FY27, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The recording has been made publicly accessible via the company's official web portal.
Investor Presentation- Q2 & H1 FY27
Investor Presentation · 02 Nov 2026, 1:21 pm
IOL Chemicals Reports Strong Q2 FY27 Financial Results and Growth Initiatives IOL Chemicals reported standalone revenue of ₹795.0 Cr for Q2 FY27, up 40.1% YoY (5.1% QoQ), while EBITDA jumped 79.6% YoY to ₹114.9 Cr with margins expanding to 14.4%. PAT surged 116.8% YoY to ₹65.0 Cr. For H1 FY27, revenue reached ₹1551.3 Cr (+38.6% YoY) and PAT stood at ₹129.5 Cr (+102.5% YoY). The company announced a ₹495 Cr capex program across three strategic projects: expanding Ibuprofen capacity by 6,000 MTPA (₹350 Cr), entering CDMO formulations (₹110 Cr), and a specialty chemicals tolling unit (₹35 Cr).
Press Release
Press Release · 31 Oct 2026, 1:37 am
IOL Chemicals Posts Record Q2 FY27 Results Driven by Margin Expansion IOL Chemicals reported record standalone Q2 FY27 revenue of ₹795.0 Cr, up 40.1% YoY, with EBITDA surging 79.6% YoY to ₹114.9 Cr. EBITDA margin expanded 321 bps YoY to 14.4%, supported by better product mix and operating efficiencies. PAT jumped 116.8% YoY to ₹65.0 Cr, with PAT margin rising 290 bps to 8.1%. Pharmaceuticals revenue reached ₹472.8 Cr, with non-Ibuprofen sales growing ~70% YoY to contribute 45% of segment revenue. Chemicals revenue rose to ₹322.3 Cr, driven by improved realisations.
Outcome of the Board Meeting and submission of Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2026
Outcome · 30 Oct 2026, 11:32 pm
IOL Chemicals Posts Strong Q2 Performance with Net Profit Surging Over 117% YoY IOL Chemicals and Pharmaceuticals reported a 40.09% YoY increase in consolidated revenue from operations to ₹795.03 crore for the quarter ended 30th Sep'26, up from ₹567.53 crore in the corresponding prior-year period. Consolidated profit after tax jumped 117.12% YoY to ₹65.07 crore against ₹29.97 crore, driven by robust performance across segments. Pharmaceutical segment revenue rose 40.55% YoY to ₹472.75 crore, while Chemical segment revenue expanded 38.31% YoY to ₹394.49 crore. Diluted EPS for the quarter improved significantly to ₹2.22 from ₹1.02 YoY.
Submission of Financial Results
Financial Result · 30 Oct 2026, 11:29 pm
IOL Chemicals & Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 795 (+40.1% YoY | +5.1% QoQ) ■ EBITDA: 109 (+91.7% YoY | +5.7% QoQ) ■ EBITDA Margin (%): 13.8 (+371 bps YoY | +8 bps QoQ) ■ PAT: 65.1 (+117.1% YoY | +1.0% QoQ) ■ EPS (INR): 2.22 (+117.6% YoY | +1.4% QoQ) IOL Chemicals & Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) Segmental Performance Pharmaceutical ■ Revenue: 473 (+40.5% YoY | +0.7% QoQ) ■ EBIT: 68.1 (+92.0% YoY | -1.1% QoQ) ■ EBIT Margin (%): 14.4 (+386 bps YoY | -26 bps QoQ) Chemical ■ Revenue: 394 (+38.3% YoY | +8.1% QoQ) ■ EBIT: 23.2 (+359.0% YoY | +33.8% QoQ) ■ EBIT Margin (%): 5.9 (+411 bps YoY | +113 bps QoQ)
IOL Chemicals and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 30 Oct 2026, 11:28 pm
Schedule of analyst / investor conference call - Q2 & H1 FY27
Intimation · 02 Nov 2026, 11:30 am
IOL Chemicals Schedules Q2 and H1 FY27 Earnings Call on 2nd Nov'26 IOL Chemicals and Pharmaceuticals Limited will host an analyst and investor conference call on 2nd Nov'26 at 11:30 AM IST to discuss financial results for the quarter and half-year ended 30th Sep'26. The call will feature key management participants, including CFO Pardeep Kumar Khanna, Sr. VP & Company Secretary Abhay Raj Singh, Director Works Kushal Kumar Rana, and Finance Advisor & Strategic Head Rakesh Mahajan. Dial-in access is available through primary domestic lines (+91 22 6280 1550 / +91 22 7115 8378) and international toll-free numbers.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 30 Oct 2026, 5:30 am
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 30-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 30 Oct 2026, 5:30 am
IOL Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve the Un-audited ....
Intimation · 30 Oct 2026, 5:30 am
IOL Chemicals Board Meeting Scheduled for 30th Oct'26 Financial Results IOL Chemicals and Pharmaceuticals Limited has scheduled a meeting of its Board of Directors on 30th Oct'26 to consider and approve the un-audited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the insider trading window, closed since 1st Oct'26, will reopen on 2nd Nov'26, 48 hours post the public dissemination of the financial results.
CEP for Fenofibrate - Process II
Others (Uncategorized) · 25 Sept 2026, 6:42 pm
IOL Chemicals Receives EDQM CEP Approval for Fenofibrate Process II The European Directorate for the Quality of Medicines & HealthCare (EDQM) granted a Certificate of Suitability (CEP) on 24th Sep'26 to IOL Chemicals and Pharmaceuticals Limited for its API product "FENOFIBRATE – Process II". This approval comes in addition to the company's existing CEP for Fenofibrate. Process II was developed to meet specific customer requirements, strengthening IOL Chemicals' regulatory compliance and expanding its supply capabilities across regulated markets.
EU-REACH Registration for Triacetin
Others (Uncategorized) · 23 Sept 2026, 9:37 pm
IOL Chemicals Receives EU-REACH Registration for Triacetin IOL Chemicals and Pharmaceuticals Limited announced on 23rd Sep'26 that it has received REACH certification/registration from the European Chemicals Agency (ECHA) for its product Triacetin under the EU-REACH framework. The regulatory approval enables the company to export Triacetin across all European Union member states. This development strengthens the company's regulatory compliance, unlocks direct access to European markets, and supports its ongoing strategic focus on expanding its global market footprint through key international product registrations.
Schedule of Analyst/Institutional Investor Meeting
Intimation · 23 Sept 2026, 5:45 pm
IOL Chemicals to Attend Bharat Connect Conference on 29th Sep'26 IOL Chemicals and Pharmaceuticals Limited announced that its management will participate in an institutional investor interaction at the "Bharat Connect Conference: Rising Stars-September 2026," organized by Arihant Capital Markets Ltd on 29th Sep'26. The engagement will be conducted virtually as a group meeting. The company stated that discussions will focus strictly on past financial results and publicly available information, with no unpublished price-sensitive information being shared.
Schedule of Analyst/Institutional Investor Meeting
Intimation · 23 Sept 2026, 5:39 pm
IOL Chemicals Schedules Virtual Investor Group Meeting for 28th Sep'26 IOL Chemicals and Pharmaceuticals Limited announced an interaction with investors and analysts scheduled for Mon, 28th Sep'26. The engagement will be a virtual group meeting organized by Nuvama PCG. Management confirmed that discussions will be restricted to past financial performance and publicly available information, ensuring no unpublished price-sensitive information is shared.
Dispatch of Reminder letter to Shareholders to Update KYC
Others (Uncategorized) · 21 Sept 2026, 10:55 pm
IOL Chemicals Dispatches KYC Reminder Letters to Physical Shareholders IOL Chemicals and Pharmaceuticals Limited announced that, pursuant to Regulation 30 of SEBI LODR Regulations, 2015, it completed the dispatch of reminder letters on 19th Sep'26 to identified shareholders holding equity shares in physical mode. Under SEBI mandates, physical security holders are required to update their PAN, contact details, bank account information, specimen signatures, and nomination choices via registrar Alankit Assignments Limited. Non-compliance restricts service requests, grievance lodging, and electronic dividend or corporate action payouts, alongside reminders to dematerialize physical holdings.
Transcript of Business Update Call with Investors and Analysts
Transcript · 17 Sept 2026, 10:33 pm
IOL Chemicals Outlines INR 500 Crore Capex Across Strategic Growth Initiatives IOL Chemicals is investing ~INR 500 crore via internal accruals across three initiatives to drive an incremental 25–30% top-line growth by FY29 and achieve >15% company-wide ROCE. Capex includes expanding fully backward-integrated Ibuprofen capacity by 6,000 MTPA to 18,000 MTPA (commissioning Dec'27), entering CDMO formulations with a 1,500 million tablets/annum EU-GMP certified facility (commercializing Q3 FY27), and setting up a dedicated specialty chemical tolling facility. Around 30% of funds are already deployed, with full utilization of new facilities targeted over 18–24 months post-commissioning.
Audio Recording of Business Update Call with Investors and Analysts
Audio / Video · 11 Sept 2026, 11:23 pm
IOL Chemicals Releases Audio Recording for Business Update Conference Call IOL Chemicals and Pharmaceuticals Limited has made available the audio recording of its Business Update Conference Call conducted with investors and analysts on 11th Sep'26. The disclosure complies with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, providing market participants access to the latest operational and strategic updates directly via the company's website.
Business Update Conference Call to discuss the Company's recent business developments and strategic growth initiatives with investors and analysts
Intimation · 10 Sept 2026, 8:40 pm
IOL Chemicals Schedules Urgent Business Update Call for 11th Sep'26 IOL Chemicals and Pharmaceuticals Limited will host a virtual business update conference call with investors and analysts on 11th Sep'26 at 3:00 PM IST. The management team—including CFO Pardeep Kumar Khanna, Director Works Kushal Kumar Rana, and Strategic Head Rakesh Mahajan—will discuss recent business developments and strategic growth initiatives. The company scheduled the interaction at shorter notice due to the urgent nature of the operational update, utilizing regulatory exemptions from the standard two-day advance notification requirement under SEBI Listing Regulations.
Expansion of Ibuprofen Capacity, New CDMO Business for Pharmaceutical Formulation and Dedicated Specialty Chemicals Manufacturing Facility
Others (Uncategorized) · 09 Sept 2026, 8:03 pm
IOL Chemicals Announces ₹495 Cr Capex for Capacity Expansion and Business Diversification IOL Chemicals and Pharmaceuticals Limited announced capex initiatives totaling ~₹495 Cr, funded entirely via internal accruals. The company is expanding its backward-integrated Ibuprofen capacity at Barnala from 12,000 MTPA to 18,000 MTPA with a ₹350 Cr outlay, target commercialization by Dec'27. Additionally, it diversified into pharma formulations CDMO via a 1,500 million tablets/annum facility (₹110 Cr capex) with Hungary GMP approval, operational in Q3 FY'27. It also committed ₹35 Cr for a dedicated specialty chemicals tolling facility for a global client, commercializing in Q3 FY'27.
Voting Results and Scrutinizer''s Report
Annual General Meeting · 02 Sept 2026, 9:46 pm
IOL Chemicals Passes All Resolutions at 39th AGM on 2nd Sep'26 IOL Chemicals and Pharmaceuticals held its 39th AGM on 2nd Sep'26, successfully passing all three ordinary resolutions. Shareholders unanimously adopted the FY26 standalone and consolidated audited financial statements. The reappointment of retiring director Kushal Kumar Rana was approved with 93.43% votes in favour and 6.57% against, reflecting minor opposition. Furthermore, the company secured near-100% shareholder approval to ratify the Cost Auditor's remuneration for the fiscal year ending 31st Mar'27. All voting proceedings were conducted seamlessly via remote e-voting in strict compliance with SEBI regulations.
Outcome of the AGM
Annual General Meeting · 02 Sept 2026, 8:29 pm
Schedule of Analyst/Institutional Investor Meeting
Intimation · 26 Aug 2026, 9:48 pm
IOL Chemicals Announces Upcoming Institutional Investor Meeting IOL Chemicals and Pharmaceuticals (IOLCP) management will attend a corporate access event organised by Phillip Capital (India) on 3rd Sep'26. The event, titled "Market Marvel - Investing Beyond the Headlines," will consist of in-person, one-on-one meetings with institutional investors and analysts. Discussions will be restricted to publicly available information and past financial results, with no unpublished price-sensitive information (UPSI) to be disclosed. The schedule is subject to change.
Earning Call Transcript
Transcript · 20 Aug 2026, 9:59 pm
Audio Recording of Analysts/Investors Call pertaining to the Financial Results Q1- FY2027
Audio / Video · 13 Aug 2026, 10:53 pm
IOL Chemicals Provides Audio Recording of Q1 FY2027 Analyst Call IOL Chemicals and Pharmaceuticals (NSE: IOLCP) has released the audio recording of its analyst and investor call held on 13th Aug'26. The call discussed the company's financial performance for the first quarter of fiscal year 2027 (Q1 FY27). The recording is available via a link provided in the exchange filing. This follows SEBI regulations and offers stakeholders direct access to management's discussion and outlook following the results announcement.
Investor Presentation
Investor Presentation · 12 Aug 2026, 10:25 pm
IOL Chemicals Reports Robust Q1 FY27 with Strong YoY Growth IOL Chemicals reported strong Q1 FY27 results with revenue from operations at ₹756.3 Cr, up 37.1% YoY, and PAT at ₹64.5 Cr, a significant 89.9% YoY increase. EBITDA grew 60.7% YoY to ₹111.7 Cr, with the EBITDA margin expanding to 14.6% from 12.4% in Q1 FY26. Both Pharmaceuticals and Chemicals segments showed solid YoY revenue growth. For FY27, the company guides for 15%-20% revenue growth, an EBITDA margin of 14%-15%, and capex of ₹200-250 Cr.